The State of Biotech 2026
The world of biotech is showing strong signs of growth and clinical impact while also experiencing new challenges. The explosion of AI is reshaping areas from drug discovery and protein folding to gene editing and clinical trials. In GEN ’s flagship virtual event we hear from a distinguished group of business executives, award-winning scientists, and journalists. The post The State of Biotech…
John Maraganore, a co-founder and executive chair of City Therapeutics, is a prominent figure in biotech. He led Alnylam Pharmaceuticals for nearly two decades, transforming it into a global leader in RNAi therapeutics. Under his leadership, Alnylam raised over $7.5 billion in capital, formed numerous alliances, and generated more than $25 billion in market capitalization.
Before Alnylam, Maraganore held key positions at Millennium Pharmaceuticals and Biogen, where he invented and developed ANGIOMAX for injection. He currently serves as CEO and principal of JMM Innovations and is active on various biotech boards. Jeremy Levin, co-founder and executive chairman of Ovid Therapeutics, brings a wealth of experience in the biopharmaceutical industry.
Prior to Ovid, Levin served as president and CEO of Teva Pharmaceutical Industries and was a key architect of the String of Pearls Strategy at Bristol Myers Squibb, driving significant growth in immunotherapy. He also held roles at Novartis and BMS, enhancing his expertise in strategic alliances and innovation. Levin is currently the chairman of Ceryvyn Therapeutics and serves on the BIO board, having previously chaired it from 2017 to 2019.
Shweta Maniar, Director of Healthcare & Life Sciences at Google Cloud, provides insights into the role of technology in advancing biotech innovations.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
